Literature DB >> 2360822

Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis.

X Sáez-Llorens1, O Ramilo, M M Mustafa, J Mertsola, C de Alba, E Hansen, G H McCracken.   

Abstract

Pentoxifylline has been shown to decrease endotoxin-induced tumor necrosis factor alpha production and reverse the inflammatory actions of interleukin-1 (IL-1) and tumor necrosis factor on leukocyte function. Because of the potential role of this cytokine-leukocyte interaction in the pathogenesis of bacterial meningitis, we investigated the ability of pentoxifylline to modulate meningeal inflammation in the rabbit meningitis model. Pentoxifylline treatment (initially an intravenous injection of 20 mg/kg followed by 6 mg/kg per h) started 20 min before intracisternal injection of 20 ng of Haemophilus influenzae type b lipooligosaccharide (endotoxin) reduced significantly concentrations in cerebrospinal fluid of leukocytes (P less than 0.0001), protein (P less than 0.001), and lactate (P less than 0.001) during the 9-h infusion compared with values in intravenous-saline-treated rabbits. When pentoxifylline was given 1 h after H. influenzae type b endotoxin, the mean peak lactate and leukocyte concentrations in cerebrospinal fluid were significantly lower than those in control animals. Pentoxifylline also significantly decreased lactate and protein concentrations (P less than 0.05) and tended to diminish leukocyte counts (P = 0.08) compared with results in control animals after antibiotic-induced release of endotoxin in animals with H. influenzae meningitis. In this regard, dexamethasone was superior to pentoxifylline and no synergism was observed when the drugs were combined. Additionally, pentoxifylline attenuated meningeal inflammatory changes induced by intracisternal inoculation of 10 ng of rabbit recombinant IL-1 beta compared with results in either dexamethasone- or saline-treated animals. We conclude that pentoxifylline is effective in this animal model in modulating the meningeal inflammatory response following intracisternal inoculation of H. influenzae type b endotoxin or organisms or rabbit recombinant IL-1beta.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360822      PMCID: PMC171702          DOI: 10.1128/AAC.34.5.837

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components.

Authors:  I Riesenfeld-Orn; S Wolpe; J F Garcia-Bustos; M K Hoffmann; E Tuomanen
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

2.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline.

Authors:  R M Strieter; D G Remick; P A Ward; R N Spengler; J P Lynch; J Larrick; S L Kunkel
Journal:  Biochem Biophys Res Commun       Date:  1988-09-30       Impact factor: 3.575

3.  Induction of meningeal inflammation by outer membrane vesicles of Haemophilus influenzae type b.

Authors:  M M Mustafa; O Ramilo; G A Syrogiannopoulos; K D Olsen; G H McCracken; E J Hansen
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

4.  Enhancement of chemotaxis and protection of mice from infection.

Authors:  G W Sullivan; T N Patselas; J A Redick; G L Mandell
Journal:  Trans Assoc Am Physicians       Date:  1984

5.  Attenuation of acute lung injury in septic guinea pigs by pentoxifylline.

Authors:  A Ishizaka; Z H Wu; K E Stephens; H Harada; R S Hogue; P T O'Hanley; T A Raffin
Journal:  Am Rev Respir Dis       Date:  1988-08

6.  Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog.

Authors:  C H Welsh; D Lien; G S Worthen; J V Weil
Journal:  Am Rev Respir Dis       Date:  1988-11

7.  Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor.

Authors:  D E Hammerschmidt; D Kotasek; T McCarthy; P W Huh; G Freyburger; G M Vercellotti
Journal:  J Lab Clin Med       Date:  1988-08

8.  Brain injury, edema, and vascular permeability changes induced by oxygen-derived free radicals.

Authors:  P H Chan; J W Schmidley; R A Fishman; S M Longar
Journal:  Neurology       Date:  1984-03       Impact factor: 9.910

9.  Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease.

Authors:  T Di Perri; O Carandente; A Vittoria; M Guerrini; G L Messa
Journal:  Angiology       Date:  1984-07       Impact factor: 3.619

Review 10.  The effect of pentoxifylline in septic shock--new pharmacologic aspects of an established drug.

Authors:  M M Schönharting; U F Schade
Journal:  J Med       Date:  1989
View more
  15 in total

1.  Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-alpha, IL-1 beta IL-10 by human leucocytes.

Authors:  A M van Furth; E M Verhard-Seijmonsbergen; R van Furth; J A Langermans
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

Review 2.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

3.  Enhanced attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD18 monoclonal antibodies and dexamethasone in experimental Haemophilus meningitis.

Authors:  X Sáez-Llorens; H S Jafari; C Severien; F Parras; K D Olsen; E J Hansen; I I Singer; G H McCracken
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 4.  Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy.

Authors:  A M van Furth; J J Roord; R van Furth
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

5.  Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms.

Authors:  L Ostrosky-Zeichner; J L Soto-Hernandez; V Angeles-Morales; F Teixeira; C Nava-Ruiz; C Rios; F Solis; J Sotelo
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 6.  Pathogenesis and pathophysiology of bacterial meningitis.

Authors:  A R Tunkel; W M Scheld
Journal:  Clin Microbiol Rev       Date:  1993-04       Impact factor: 26.132

7.  Protective effect of pentoxifylline plus thalidomide against septic shock in mice.

Authors:  O Arrieta; A Ortiz-Reyes; D Rembao; M Calvillo; E Rivera; J Sotelo
Journal:  Int J Exp Pathol       Date:  1999-02       Impact factor: 1.925

8.  Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans.

Authors:  K Miller; A Louie; A L Baltch; R P Smith; P J Davis; M A Gordon
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

9.  Effect of dexamethasone or HWA-138 in combination with antibiotics in experimental Haemophilus influenzae type b infection.

Authors:  A F Rodriguez; S L Kaplan; E P Hawkins; E O Mason
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

10.  Effect of xanthine derivates and dexamethasone on Streptococcus pneumoniae-stimulated production of tumor necrosis factor alpha, interleukin-1 beta (IL-1 beta), and IL-10 by human leukocytes.

Authors:  A M van Furth; E M Seijmonsbergen; J A Langermans; P H van der Meide; R van Furth
Journal:  Clin Diagn Lab Immunol       Date:  1995-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.